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Abstract
Background: The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) is widely expressed throughout the
vertebrate nervous system, including the pain processing neuraxis. Inhibitors of NAAG peptidases are analgesic in
animal models of pain. However, the brain regions involved in NAAG’s analgesic action have not been rigorously
defined. Group II metabotropic glutamate receptors (mGluR2/3) play a role in pain processing in the laterocapsular
part of the central nucleus of the amygdala (CeLC). Given the high concentration of NAAG in the amygdala and its
activation of group II mGluRs (mGluR3 > mGluR2), this study was undertaken using the mouse formalin model of
inflammatory pain to test the hypothesis that NAAG influences pain processing in the amygdala. Evoked excitatory
postsynaptic currents (eEPSCs) were studied in neurons in the CeLC of mouse brain slices following stimulation of
the spinoparabrachial amygdaloid afferents.
Results: Application of a NAAG peptidase inhibitor, ZJ43, dose dependently inhibited the amplitude of the eEPSCs
by up to 50% in control CeLC demonstrating the role of NAAG in regulation of excitatory transmission at this
synapse. A group II mGluR agonist (SLx-3095-1) similarly inhibited eEPSC amplitude by about 30%. Both effects
were blocked by the group II mGluR antagonist LY341495. ZJ43 was much less effective than SLx in reducing
eEPSCs 24 hours post inflammation suggesting an inflammation induced reduction in NAAG release or an increase
in the ratio of mGluR2 to mGluR3 expression. Systemic injection of ZJ43 proximal to the time of inflammation
blocked peripheral inflammation-induced increases in synaptic transmission of this pathway 24 hrs later and
blocked the induction of mechanical allodynia that developed by this time point.
Conclusions: The main finding of this study is that NAAG and NAAG peptidase inhibition reduce excitatory
neurotransmission and inflammation-induced plasticity at the spinoparabrachial synapse within the pain processing
pathway of the central amygdaloid nucleus.
Background
The peptide neurotransmitter N-acetylaspartylglutamate
(NAAG) has a positive role in animal models of trau-
matic brain injury, stroke, schizophrenia, inflammatory
pain and peripheral neuropathy (reviewed in [1,2]).
NAAG is widely distributed in the brain and spinal
cord, including the ascending and descending pain path-
ways [3,4]. NAAG activates group II metabotropic gluta-
mate receptors (mGluR3 >m G l u R 2)[ 5 - 7 ] .T w o
enzymes, glutamate carboxypeptidase II and III (GCPII
and GCPIII), that inactivate synaptically released NAAG
have been cloned and characterized [8-10] and a series
of NAAG peptidase inhibitors have been developed
[2,11]. These inhibitors have been used to define the
effects of synaptically released NAAG in vivo.
Systemic, local and central applications of the NAAG
peptidase inhibitors are analgesic in inflammatory and
neuropathic pain models, an effect that is reversed by
systemic administration of the group II mGluR antago-
nist, LY341495 [12-16]. It is hypothesized that NAAG
exerts its analgesic effects by reducing glutamate release
via the presynaptic group II mGluRs [1]. NAAG pepti-
dase inhibition reduced synaptic release of glutamate at
an identified synapse in the hippocampus, consistent
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[17,18]. However, there have been no direct demonstra-
tions of the actions of endogenous NAAG at other iden-
tified synapses, including those in the pain processing
pathway.
The amygdala is involved in affective processing of
sensory information including pain-related responses
[19-22]. The central nucleus (CeA) is the main output
of the multinucleated amygdaloid complex; its connec-
tions make it critical for expression of pain-related
responses [19,21,23,24]. A glutamatergic synaptic path-
way in the laterocapsular part of the central nucleus
amygdala (CeLC) is involved in inflammatory pain pro-
cessing [25]. Activation of the group II mGluRs signifi-
cantly inhibited the evoked excitatory postsynaptic
current (eEPSCs) in the CeLC in the rat arthritic model
of inflammatory pain [26,27]. Given the expression of
NAAG and NAAG peptidase activity in the amygdala
[28-30], we speculated that NAAG activation of presy-
n a p t i cg r o u pI Ir e c e p t o r si nt h eC e L Cp l a y sar o l ei n
regulating transmitter release and that elevation of
synaptic levels of NAAG influences processing of
inflammatory pain signals [1].
The NAAG peptidase inhibitor, ZJ43, was used to
define the peptide’s role in the spinoparabrachial amyg-
daloid afferent synapses in the CeA in brain slices from
mice prior to and at different intervals after induction of
footpad inflammation.
Results
Prolonged nociceptive behaviors in formalin mice model
Thermal hypersensitivity in formalin model
Thermal withdrawal latency (TWL) response was
repeatedly assessed in each mouse using the Hargreaves
apparatus prior to and at 1, 3, 6 and 24 hours post
injection into the footpad (saline- and formalin-injected
groups). Thermal withdrawal latency (TWL) was signifi-
cantly decreased at 1 and 3 hours post peripheral
inflammation relative to saline treated (1 hr, p = 0.003;
3h r ,p=0 . 0 2 )o rn a ï v e( u n i n j e c t e d )m i c e( 1h r ,p<
0.001; 3 hr, p = 0.04) (Figure 1A). The saline treated
and naive mice habituated to the repeated testing and
were no different from formalin treated mice at 6 hours
(~70% baseline TWL for all groups). Both saline and
formalin treated mice responses returned to baseline
values by 24 hours.
Mechanical hypersensitivity in formalin model
Mechanical withdrawal threshold (allodynia) was repeat-
edly assessed in each mouse using the electronic von
Frey anesthesiometer (EVF) system prior to and at 1, 6
and 24 hours post injection into the mouse’s footpad
(saline and formalin groups). The formalin treated mice
exhibited prolonged mechanical allodynia in the injected
left hindpaw that was significant at 1, 6 and 24 hours
compared to baseline, while the contralateral hindpaw
gave a significantly lower threshold response at 24 hours
p o s ti n j e c t i o nc o m p a r e dt ob a s e l i n eb u tn o ta t1a n d6
hours. In contrast, the saline treated mice did not show
any significant reduction in the threshold response (Fig-
ure 1B). The mechanical thresholds of the formalin
injected hindpaws were significantly lower than those
observed in the saline-injected animals at all time points
post injection (p ≤ 0.05).
ZJ43 treatment prevents the development of mechanical
allodynia in the formalin mice model
After baseline trials, two doses of NAAG peptidase inhi-
bitor ZJ43 (150 mg/kg) was administered intraperitone-
ally (I.P.) 30 minutes prior to and approximately 8
hours after formalin injection into the mouse’s footpad.
This treatment inhibited peptidase activity for no more
than 16 hours but not at 24 hour testing time (see
Methods). The mechanical withdrawal threshold was
then assessed at 24 hours post formalin treatment.
NAAG peptidase inhibition blocked the development of
mechanical allodynia in the injected hindpaw while the
effect of ZJ43 failed to reach significance (p = 0.13) in
the contralateral hindpaws at the 24 hr time point (Fig-
ure 1B).
Peripheral inflammation results in synaptic changes in
the CeLC region of the formalin mice model
Enhanced synaptic transmission in brain slices from
formalin-treated mice
To determine whether the behavioral changes observed
are parallel with in vitro alterations in neuronal trans-
mission in the laterocapsular part of the central nucleus
of amygdala (CeLC), input-output experiments were
conducted on mouse brain slices in standard ACSF at 1
and 6 hours post peripheral inflammation. The input
output function of synaptic transmission was obtained
by measuring the output current as a function of stimu-
lus intensity. The magnitude of the evoked current was
significantly increased 6 hours but not 1 hour after for-
malin injection relative to uninjected control experi-
ments (Figure 2A &2B). When the input-output
experiments were repeated in nominally Mg
2+ free
ACSF recording solution at 6 and 24 hours after induc-
tion of peripheral inflammation, a significant gain in the
current output was observed as a function of stimulus
intensity (Figure 2C &2D).
NMDA/AMPA ratio remain unchanged in brain slices from
formalin-treated mice
CPP (10 μM), a NMDA receptor antagonist, was used to
pharmacologically evaluate the contribution of postsy-
naptic AMPA and NMDA receptors to the enhanced
current observed in the input-output experiment at 24
hours post inflammation. The evoked currents in the
presence of CPP were digitally subtracted offline from
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Figure 1 Prolonged nociceptive behaviors in formalin mice model.( A) Baseline thermal withdrawal latency (TWL) was determined for each
mouse prior to treatment. This value was used to establish 100% baseline for that subject. Control groups (saline and naïve) mice showed
habituation when retested at 3 and 6 hours. Thermal hypersensitivity (lower TWL relative to baseline as 100%) is observed in the formalin treated
mice (n = 15) compared to the control groups (saline-treated n = 11; naïve n = 10) at 1 and 3 but not 6 hours post injection. The formalin
treated group TWL was significantly different at 1 hr compared to naïve (p < 0.001) and (p < 0.005) saline groups; at 3 hr compared to saline
(p < 0.02) and naïve (p < 0.05) groups. TWL returns to baseline values at 24 hours in the treated groups. #p ≤ 0.05 across group comparison for
TWL values by two way RM-ANOVA followed by pairwise Tukey t-test post hoc analysis. (B) Mechanical allodynia, measures as paw withdrawal in
response to force of probe in grams, was assessed in the injected hindpaws (ipsilateral = injected paw, IP) and opposite (contralateral, CL)
hindpaws. There was a significant difference between the ipsilateral and contralateral footpad (p < 0.02) in the formalin mice. Ipsilateral hindpaw
allodynia was significant at 1, 6 and 24 hours post-inflammation relative to the baseline values (n = 15). At 24 hours post-inflammation, the
contralateral threshold was significantly (p < 0.05) lower compared to the baseline values in the contralateral footpad. ZJ43 (150 mg/kg; IP, n =
10) administered 30 prior to and 8 hours post formalin injection significantly reduced allodynia in the ipsilateral footpad (∞p ≤ 0.05, ZJ43
(formalin)-IP vs. Formalin-IP mechanical withdrawal threshold values at 24 hr post inflammation). The difference between ZJ43 (formalin)-CL and
Formalin-CL did not reach statistical significance (p = 0.13). Two way RM-ANOVA was used followed by pairwise Tukey t-test post hoc analysis.
Baseline (B) = probe force that induced paw withdrawal in mice prior to injection of formalin or saline. Data presented as mean ± SEM, *p ≤
0.05 vs. baseline values; was used followed by pairwise Tukey t-test post hoc analysis.
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Figure 2 Enhanced synaptic transmission in the CeLC nucleus of control and formalin brain slices. Enhanced evoked current was
observed in the central amygdala, laterocapsular part (CeLC) neurons 6 and 24 hours after peripheral inflammation. Input-output experiments
were conducted to examine neurotransmission changes in the CeLC as a result of peripheral inflammation (QX-314 [5 mM] local anesthetic was
included in the pipette solution). (A) Representative trace depicting evoked response at maximal stimulation intensity in cells from untreated
control and formalin treated animals 1 and 6 hours post inflammation (standard ACSF).(B) An increase in current output was observed at 6 hours
(n = 6) and not 1 hour (n = 9-13) in the CeLC post inflammation.(C) Representative trace depicting evoked response at maximal stimulation
intensity in cells from untreated control and formalin treated animals 6 and 24 hours post inflammation (Mg
2+ Free ACSF). (D) There was a
significant gain in the current output at 6 (n = 13) and 24 hours (n = 12) in the CeLC following inflammation. (E) Representative trace depicts
how NMDA/AMPA ratio was obtained. NMDAR antagonist, CPP (10 μM), was used to determine the relative contribution of the NMDA and
AMPA components of the evoked current response during input-output experiments (Mg
2+ Free ACSF). (F) NMDA/AMPA ratio was unchanged in
the CeLC 24 hours after inflammation [control (n = 6), formalin 24 hours (n = 11)]. Data presented as mean ± SEM, *p ≤ 0.05 vs. control,
Student’s t-test.
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component (Figure 2E). The observed current ranged
from 10 to 800 pA but are not reported because the
current output depended on the stimulus intensity. As a
result, analysis of the NMDA/AMPA ratio was used
because it allows for comparison between cells. The
NMDA/AMPA ratio was not significantly changed 24
hours post inflammation compared to that obtained in
uninjected control mice (Figure 2F).
Increased excitability of neurons in brain slices from
formalin-treated mice
Following the observation of enhanced current output in
the CeLC region, changes in the intrinsic firing proper-
ties of the neurons as a consequence of peripheral
inflammation were investigated with current clamp
recordings (Figure 3A control and 3B after inflamma-
tion). Neurons were injected with increasing depolariz-
ing currents (20 pA steps, 200 ms) and the action
potential firing rates were analyzed. Increased action
potential firing rates were observed in the CeLC 24
hours after peripheral inflammation (Figure 3C). Mean
input resistances were 197 ± 13.4 MΩ for control
untreated mice (n = 31) and 225 ± 31.4 MΩ for forma-
lin treated mice (n = 30) (p = 0.3, unpaired t-test). The
rheobase current (see methods) for the formalin 24 hr
group was lower but not significantly different from the
uninjected control group (Control 41 ± 8 pA, n = 28;
Formalin 29 ± 5 pA, n = 18 p = 0.2, unpaired t-test).
The increased firing rate and the enhanced evoked
current suggest that in addition to an increase in trans-
mitter release in the CeLC as a consequence of periph-
eral inflammation, there also were changes in the
excitability of postsynaptic neurons (Figure 2D &3C).
NAAG peptidase inhibition, NAAG and group II mGluR
agonist affect synaptic transmission in the CeLC of
control mouse
ZJ43 inhibits synaptic transmission in the CeLC
To define the role of endogenous NAAG on modulating
glutamate release in the laterocapsular part of the amyg-
dala (CeLC), the NAAG peptidase inhibitor ZJ43 was
locally applied to the brain slice to prolong synaptic
availability of NAAG following its release. ZJ43 treat-
ment resulted in a maximal reduction in EPSC of 50%
at 10 μM (Figure 4). Control experiments were con-
ducted for the same duration as the dose response
experiments; no significant change was observed in the
amplitude of the evoked current over time (representa-
tive trace shown in lower panel, Figure 4A). Based on
t h ed o s er e s p o n s eo b s e r v a t i o n s ,0 . 1μM ZJ43 (approxi-
mately half maximal dose) was used to study the role of
endogenous NAAG in the CeLC region.
In brain slices obtained from untreated control mice,
0.1 μMZ J 4 3r e s u l t e di nas i g n i f i c a n tr e d u c t i o n( ~ 3 0 % )
in the amplitude of the evoked current (Figure 5A,
upper traces; Figure 5B). This indirect inhibitory effect
of ZJ43 was blocked by co-application of LY341495 (1
μM), a competitive group II mGluRs antagonist. Similar
effects of ZJ43 and LY341495 were obtained in the stan-
dard ACSF recording solution (Figure 5A, lower traces,
and 5B).
To validate the effect of ZJ43 at this synapse, repuri-
fied NAAG (1 μM )a n dt h eg r o u pI Im G l u Ra g o n i s t
SLx-3095-1 (0.5 μM) were applied locally to the slice in
nominally Mg
2+ free and standard ACSF recording con-
ditions. NAAG and Slx-3095-1 caused a significant
reduction in the amplitude of the evoked current (Figure
5C, left traces; 5D). To determine whether the group II
mGluRs are tonically activated in the CeLC region of
the uninjected control mice brain slice, the group II
mGluR antagonist LY341495 (1 μM) was applied locally
to the slice preparation in both Mg
2+ free and standard
ACSF solutions. The antagonist had no significant effect
on the amplitude of the evoked current in these control
preparations in either recording solutions (Figure 5E
and 5F; MgCl2, p = 0.76; Mg
2+ Free conditions p = 0.74)
suggesting minimal activation of the group II mGluRs in
the CeLC region of the brain slice at low stimulation
frequency (0.1 Hz) in control mice.
To address NAAG’s proposed presynaptic modulatory
site of action, ZJ43’s effect on miniature spontaneous
EPSCs was determined in the presence of 0.5 μMT T X
and 10 μM CPP to block sodium dependent action
potentials and NMDA current respectively (Figure 6A).
Application of 0.1 μM ZJ43 to the CeLC region signifi-
cantly reduced the frequency of the mEPSCs (p ≤ 0.05,
paired t-test, Figures 6C, E), while it had no significant
effect on the amplitude of the mEPSCs (p = 0.32, paired
t-test) (Figure 6B, D). The difference in paired pulse
ratio (PPR) between control and ZJ43 treated cells was
not significant (control 1.52 ± 0.13 vs. ZJ43 1.62 ± 0.18,
p = 0.3 in paired t-test; wash 1.39 ± 0.10, n = 6).
Endogenous NAAG effect in the CeLC following
inflammation in the formalin mouse model
Endogenous NAAG inhibits synaptic transmission in brain
slices from formalin-treated mice 6 and 24 hours after
peripheral inflammation
Given that synaptic plasticity was observed in the CeLC
region as early as 6 hours post peripheral inflammation,
the effects of ZJ43 (0.1 μM), NAAG (1 μM), and
LY341495 (1 μM) were assessed on the amplitude of
eEPSCs at this time point. ZJ43 significantly inhibited
the amplitude of eEPSCs (Figures. 7A and 7C). Co-
application of ZJ43 with LY341495 reversed the effect of
the peptidase inhibitor’s( F i g u r e7 A ) .E x o g e n o u sN A A G
tended to reduce the eEPSC amplitude to 76 ± 9.6% of
control (p ≤ 0.05, n = 8 paired t-test, data not shown).
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Page 5 of 18In contrast to the control preparations, LY341495 alone
appeared to increase eEPSC amplitude as might be
expected if the antagonist blocked basal mGluR activa-
tion by endogenous NAAG, but this change did not
reach statistical significance (Figure 7B and 7D, p =
0.15, n = 7, paired t-test).
In contrast to its efficacy in the amygdala from control
mice (Figure 5B), ZJ43 (0.1 μM )h a dv e r yl i t t l ee f f e c t
(~5%) on the evoked current at this synapse 24 hours
after induction of inflammation (Figures 8A and 8C),
while SLx-3095-1 again caused a substantial reduction
in eEPSCs (Figures 8B and 8D).
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Figure 3 Enhanced neuronal excitability in the CeLC neurons in brain slice of formalin-treated mice. CeLC neurons in slices from
untreated control and formalin treated mice were tested 24 hours after inflammation by injection with 20 pA current steps. Example of CeLC
neuron firing patterns of untreated control (A), and formalin-treated mice (B) in response to the depolarizing current steps. (C) Average data
showing increased action potential frequency in the CeLC neurons in brain slices 24 hours after inflammatory insult compared to untreated
control [Formalin (n = 18), Control (n = 30)].(D) Average rheobase current in CeLC neurons in brain slices [Control (n = 28), Formalin (18)]. Data
presented as mean ± SEM, *p ≤ 0.05 vs. control, Student’s t-test. Recordings were in Mg
2+ free ACSF.
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Figure 5 Endogenous and applied NAAG inhibit synaptic transmission in the CeLC of the mouse amygdala.( A) Representative current
traces recorded from two neurons in the CeLC region of brain slices from untreated control mice following stimulation of the spinoparabrachial
amygdaloid afferents in the absence and presence of MgCl2 in the ACSF. ZJ43 (0.1 μM) inhibits inactivation of endogenously released NAAG and
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Page 8 of 18IP injection of peptidase inhibitor, ZJ43, reduced
inflammation-induced enhanced current output in the
central nucleus of amygdala
In this series of experiments (Figure 9), there again
was a substantial increase in eEPSC amplitude with
increasing stimulus intensity 24 hours after formalin
injection. Two doses of the NAAG peptidase inhibitor
ZJ43 (150 mg/kg, i.p.) were administered to the
formalin mice group as in the behavioral studies (Fig-
ure 1). The peptidase inhibitor completely blocked the
formalin-induced increase in the excitatory response at
at i m ew h e nt h e r ew a sl i t t l eo rn oo n g o i n gp e p t i d a s e
inhibition. This effect correlates with the findings
s h o w ni nF i g u r e1 Bi nw h i c hZ J 4 3b l o c k e dt h ed e v e l -
opment of the mechanical allodynia that was observed
24 hours post inflammation.
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Figure 6 Endogenous NAAG acts presynaptically to reduce the frequency of mEPSCs in the CeLC region. Application of ZJ43 (0.1 μM) in
the presence of TTX and CPP (to block action potentials and NMDA current respectively) in the CeLC region of the amygdala in slices from
untreated control mice significantly reduced the frequency of miniature EPSC, while the amplitude of the mEPSCs was not significantly altered.
(A) Representative current traces in the absence and presence of ZJ43 in a neuron. (B) Cumulative amplitude curve in the presence and absence
of ZJ43. (C) Cumulative inter-event interval curve depicting mEPSCs frequency rate in the presence and absence of ZJ43 in a neuron from a
control untreated mouse brain slice. Bar graph showing % control of amplitude (p = 0.3, n = 9, ZJ43 treated versus control) (D) and frequency
(E) values for cells (n = 9). Data presented as mean ± SEM, *p ≤ 0.05 vs. control, paired Student’s t-test. Recordings were in Mg
2+ free ACSF.
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induced changes in spinoparabrachial input to the cen-
tral nucleus were specific to this pain pathway rather
than generalized changes due to stress or other factors,
recordings also were made following stimulation of the
external capsule (EC) that carries cortical afferents input
to the amygdala. No change in eEPSC amplitude was
observed with increasing stimulus intensity in this cir-
cuit 24 hours after induction of inflammation (lower
panel formalin 24 hr EC vs. middle panel formalin 24 hr
PB, Figure 9A &9B). Instead a reduction in the current
output was observed when compared to that obtained in
control brain slices.
Discussion
Peptidases that inactivate NAAG have been cloned,
characterized and deleted in null mutant mice
[9,10,31,32]. Inhibitors of these peptidases and agonists
of NAAG’s mGluRs have been studied as promising tar-
gets for drug development [1,2,11,33,34]. In contrast to
other neurotransmitters, the actions of endogenously
released NAAG have been difficult to rigorously
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Figure 7 ZJ43 inhibit the evoked current in CeLC neurons 6 hours after induction of peripheral inflammation.T h eg r o u pI Im G l u R
antagonist, LY341495 (1 μM), was used to define the level of tonic activation of the receptors as a consequence of peripheral inflammation.
Representative traces: (A) ZJ43 (0.1 μM) significantly reduced eEPSCs in CeLC neurons; Average data showing (D) ZJ43 effects 6 hours post
inflammation (n = 7). (B) In a separate set of cells, the direct effect of LY341495 was tested on the evoked current in the brain slice 6 hours post
formalin treatment; (C) Average data showing LY341495 effect 6 hours post inflammation (p = 0.17, n = 7). Data presented as mean ± SEM
percent control; *p ≤ 0.05 vs. control, paired Student’s t-test. Recordings were in Mg
2+ free ACSF.
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Figure 8 The efficacy of ZJ43 and SLx-3095-1 in CeLC 24 hours post peripheral inflammation. Whole cell recordings were conducted to
investigate the inhibitory efficacy of ZJ43 (0.1 μM) and SLx-3095-1 (0.5 μM) in the CeLC 24 hours post peripheral inflammation. (A)
Representative trace of the ZJ43 effect. (C) Average data for experiments shown in A in which ZJ43 alone had very little effect on eEPSCs (5%
reduction, p < 0.01, n = 10, paired Student’s t-test in contrast to its effect in controls (Figure 4). (B) SLx-3095-1 significantly reduced the
amplitude of the eEPSCs in the CeLC region (n = 12), average data shown in (D). Data presented as mean ± SEM percent control; *p ≤ 0.05 vs.
control, paired Student’s t-test. Recordings were in Mg
2+ free ACSF.
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Figure 9 PB-CeA and not EC-CeA synapse is activated in response to peripheral inflammation. To investigate the specificity of the PB-CeA
pathway output to the inflammation, the external capsule (EC) was stimulated while recordings were made from neurons present in the CeLC
region of brain slices obtained from formalin treated animals. For these stimulus intensity experiments, the local anesthetic QX-314 (5 mM) was
included in the pipette solution. (A) The enhanced current output induced by inflammation observed after stimulation of the PB afferents
(middle panel, n = 5) did not occur when the EC was stimulated (lower panel, n = 5). Stimulation of the EC in the formalin brain slices yielded
significantly lower current magnitude at the higher intensity compared to that obtained in untreated control brain slices (upper panel, n = 4).
Injection (i.p.) of NAAG peptidase inhibitor ZJ43(150 mg/kg, n = 6, lower panel) 30 minutes before and 8 hours after formalin injection into the
mouse’s footpad significantly blocked the enhanced current output that would have occurred with stimulation of the PB afferents at the higher
stimulus intensities in the formalin group (middle panel). Larger current output albeit not significant was observed in the CeLC region of brain
slices obtained from the saline group (middle panel, n = 5) when compared to the untreated control group (upper panel, n = 5). (B) Average
data showing the current output as a function of the stimulus intensity in all four animal groups (untreated control, saline treated, ZJ43- formalin
treated, and formalin treated). For the treated groups the recordings were performed 24 hours post saline or formalin injection into the mouse’s
footpad. Afferents stimulation: (PB) indicates the parabrachial afferents, while (EC) indicates that the external capsule was stimulated. Data
presented as mean ± SEM; *p ≤ 0.05 vs. control, #p ≤ 0.05 across group (Formalin 24 hr PB vs. ZJ43 Formalin 24 hr PB and Saline 24 hr PB), ◊p ≤
0.05 across group (Formalin 24 hr PB vs. Formalin 24 hr EC),∞ p ≤ 0.05 across group (Formalin 24 hr EC vs. Control Untreated EC), unpaired
Student’s t-test. Recordings were in Mg
2+ free ACSF.
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to glutamate by peptidases in the extrasynaptic space.
Circumventing this, the application of NAAG peptidase
inhibitors to slice preparations provides an opportunity
to study the physiology of released peptide [17]. Impor-
tantly in this and previous pain studies, the effects of
ZJ43 are blocked by the group II mGluR antagonist,
LY341495, supporting the conclusion that the peptide
was acting via these receptors. The data reported here
represent the first to couple the synaptic action of
NAAG to a discrete central sensory processing pathway
in a basal state and as it changes in response to sensory
input.
These data support the hypothesis that ZJ43-mediated
increases in NAAG decreased glutamate release in the
amygdala, although this remains to be directly demon-
strated in this brain region via microdialysis studies. It is
well established, however, that group II mGluRs located
at presynaptic glutamatergic synapses decreased evoked
transmitter release [35-40]. Consistent with this, we pre-
viously used ZJ43 to elevate extracellular NAAG levels
and decrease glutamate flux from hippocampal neurons
in vivo [41]. Important to interpreting studies using
ZJ43, this peptidase inhibitor has no direct action on
group II or other mGluRs [12,42]. An alternative inter-
pretation of these data would be that the ZJ43-induced
decrease in EPSCs resulted from decreased release of
glutamate directly from NAAG hydrolysis. Militating
against this interpretation are microdialysis data demon-
strating that extracellular NAAG levels are insufficient
to significantly contribute to basal or stimulated gluta-
mate levels [41,43].
Presynaptic action of endogenous NAAG
NAAG peptidase inhibition significantly reduced the fre-
quency of the miniature excitatory currents in this pain
processing synapse in the amygdala (Figure 6E) support-
ing a presynaptic action of NAAG. The consistent
degree of inhibition of eEPSC amplitude by ZJ43 in the
presence and absence of Mg
2+ in the bathing medium
(Figure 5) provides further evidence for a presynaptic
action inasmuch as a post-synaptic action would be
unlikely to affect NMDA and AMPA currents equally. A
structurally different NAAG peptidase inhibitor similarly
reduced eEPSCs and increased the paired pulse ratio
(PPR) at the mossy fiber-Ca3 synapse [17].
The efficacy of NAAG in reducing transmitter release
supports the hypothesis that NAAG expands the
dynamic range of synapses across the nervous system by
dampening release of its different co-transmitters at
high levels of excitation. This would be a particularly
important concept under pathological states that are
associated with excessive glutamate release [1,40,41,44].
The absence of an effect of the group II mGluR
antagonist alone under the basal activity of the control
CeLC (Figure 5E, F) would be predicted by such a
dynamic range model as would the absence of neurolo-
gical deficits in GCPII knock-out mice under unstressed
conditions [31].
Peripheral formalin-induced inflammation enhances
current output in CeLC region
Elevated glutamatergic transmission in this spinoparab-
rachial amygdaloid pathway is involved in inflammatory
pain processing [21]. The parabrachial nucleus (origin of
PB-CeLC afferents) relays converging specific nocicep-
tive information from the spinal lamina I to the fore-
brain. The spinal nociceptive inputs reach, both directly
and via the parabrachial nucleus, all subcortical compo-
nents of the central autonomic network, including the
amygdala [45-48]. The amygdaloid nuclear complex pro-
vides emotional significance to sensory stimuli, including
pain [25,49,50]. Synaptic plasticity observed in the CeLC
region following formalin-induced inflammation (Figures
2 and 3) is consistent with data from the rat mono-
arthritic [51,52] and spinal nerve ligation models [53]. A
similar current increase was found in the cingulate cor-
tex after footpad inflammation [54-56]. In addition,
molecular changes, such as enhanced pERK levels, were
reported in the right CeLC amygdala region of mouse
brain slices as early as 3 hours after formalin injection
into the left or right footpad [57].
The change in efficacy of ZJ43 from control to 24 hr
post inflammation (Figure 8), while the group II agonist
remained effective under both conditions, is consistent
with either a decrease in release of NAAG at the 24 hr
point or a change in the ratio of the group II receptors
in favor of mGluR2.
In contrast to the change in the PB pathway to the
central nucleus 24 hrs after formalin injection, the EC
evoked EPSCs is substantially reduced (Figure 9A).
While this may have been due to plasticity induced by
decreased cortical input the amygdala following periph-
eral inflammation, there are insufficient published data
on cortical input to the amygdala under these conditions
to permit such speculation.
Endogenous NAAG’s role in the PB-CeA circuit
NAAG, NAAG peptidase activity and group II mGluRs
are present in the pain processing pathway [28,37-39].
While the efficacy of NAAG peptidase inhibitors in
modulating perception of inflammatory pain has been
studied extensively [14-16,58], discrete sites in the pain
pathway have not been explored systematically for the
peptide’s action. The observation that ZJ43-induced ele-
vation of NAAG has a role at the PB-CeLC synapse in
control mice supports the view that this is one site
where systemic ZJ43 might act to reduce acute
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stantially lower effect of ZJ43 24 hours after induction
of inflammation argues that NAAG peptidase inhibition
would have less influence on the PB-CeLC contributions
to long term inflammatory pain perception. However,
systemic injections of the peptidase inhibitor proximal
to the time of in formalin treatment blocked the
enhanced current output observed in the CeLC region
associated with inflammatory input (Figure 9B) and
mechanical allodynia in the injected hindpaw (Figure
1B) at the 24 hour time point. This result supports the
view that early induction of analgesia by NAAG pepti-
dase inhibition sufficiently suppresses activity in the
pain pathways of the CeLC as to preclude the induction
of this dramatic change in the circuit’se x c i t a t o r y
transmission.
Conclusions
Data from this study support the following conclusions:
(1) NAAG released at the spinoparabrachial amygdaloid
synapse (PB-CeA) inhibits evoked release of its co-trans-
mitter glutamate via presynaptic mGluRs (Figure 10); (2)
over 24 hrs following induction of peripheral inflamma-
tion, PB-CeA afferents progressively exhibit enhanced
evoked glutamate release and postsynaptic cells exhibit
greater excitability; (3) this enhanced release is blocked
by NAAG peptidase inhibition proximate to the time of
the inflammatory insult; (4) within 24 hours after onset,
peripheral inflammation induces a shift in the relative
influence of NAAG peptidase inhibition on glutamate
release at the PB-CeA synapse; (5) this inflammatory
insult induces further physiologic plasticity: allodynia in
the form of bilateral sensitivity to mechanical stimuli
after 24 hours; (6) NAAG peptidase inhibition blocks
the induction of this allodynia in the injected hindpaw.
Methods
Animals
Adult male C57BL/6 mice (postnatal day 17-25; Taco-
nic, Germantown, NY) were housed with food and
water available ad libitum in a temperature-controlled
environment with light/dark cycle of 12:12 hour. All
procedures were conducted in compliance with George-
town University’s Animal Care and Use regulations. All
experiments were performed with the approval of the
Georgetown University Animal Care and Use Commit-
tee. Effort was made to minimize the number of animals
used to avoid unnecessary suffering.
Formalin Test
Mice were anaesthetized via inhalation of 3% isoflurane
and maintained with 1.5% isoflurane while the left foot-
pad was injected. Mice recover with spontaneous activity
promptly after removal of the anesthetic. Inflammation
was induced by injecting 20 μL of 5% formalin (37% for-
maldehyde solution diluted in saline solution, 30 gauge
needle) into the intraplantar surface of the mouse’s
hindpaw [59,60]. Control mice received 20 μL of saline
solution (0.9%) into their hindpaw. Animals were moni-
tored regularly after injections.
Nociceptive testing: Thermal hyperalgesia
Hargreaves plantar apparatus (Ugo Basile, Camerio VA,
Italy) was used to assess the thermal withdrawal latency
(TWL) in the injected hindpaw [61]. Briefly, mice were
allowed to acclimate (20 minutes) within a Plexiglas
enclosure on a clear glass plate maintained at 30°C.
When the mice were stationary, a mobile radiant heat
source (i.e., high intensity projector lamp) located under
the glass table was activated with a timer and focused
onto the plantar surface of the left hindpaw. Thermal
paw-withdrawal latency was determined by a motion
detector that halted both lamp and timer when the paw
was withdrawn. A maximal cut-off of 30 s was employed
to prevent tissue damage. Paw withdrawal latencies were
recorded automatically. Naïve (uninjected control), sal-
ine-treated, and formalin-treated animals were tested.
Trials were repeated in the same animals prior to injec-
tion (baseline) and at 1, 3, 6 and 24 hours post-injection
of either formalin or saline into the left footpad. Each
Figure 10 Model of plasticity, mGluRs and NAAG in an
inflammatory pain pathway of the mouse amygdala. In the
CeLC region of the amygdala of control mouse brains, ZJ43 inhibits
CGPII (glial enzyme) and GCPIII (neuronal and glial enzyme). As a
consequence, it effectively elevates the levels of synaptically
released NAAG. The peptide acts relatively selectively at the mGluR3
to mediate its inhibition of glutamate release consistent with data
on the actions of this peptide in other systems [1].
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Page 14 of 18trial was repeated twice at 3 minutes intervals, and the
TWL is the average of the two responses. Behavioral
response of flinching that may or may not be accompa-
nied by licking of the heated paw was taken as a
response. The heat stimulus gave a basal TWL of 7.1 ±
0.1 seconds.
Nociceptive testing: Mechanical allodynia and threshold
For the evaluation of mechanical allodynia, mice were
placed individually in clear Plexiglas enclosures on ele-
vated mesh stand (large base 36” ×1 6 ”) (IITC Life
Science, Woodland hills, CA) to allow access to the sur-
face of the hindpaw. The withdrawal threshold (WT) in
grams was obtained by application of the rigid tip
attached to the anesthesiometer transducer probe (2390
series Electronic von Frey Anesthiometer (EVF), Stoelt-
ing Co, Wood Dale, IL). The EVF system allows mea-
surement and displays test readings upon reaction in
grams based upon the amount of pressure applied. The
EVF is zero calibrated before each use. When the mice
were stationary, the stimuli were delivered from below,
to the plantar surface of the hindpaw. The animals were
acclimatized for 1 hour before behavioral testing and
the mechanical allodynia was evaluated at several time-
points (1, 6, and 24 hours). In order to determine the
basal mechanical thresholds, all the groups were evalu-
ated before the test procedures. Each trial was repeated
twice at 5 minutes interval, the withdrawal threshold is
an average of the two responses. Saline treated, formalin
treated, and ZJ43- Formalin treated animals were tested.
IP Injections
ZJ43 (150 mg/kg) was administered intraperitoneally
(IP) 30 minutes prior to and approximately 8 hours
after formalin injection into the mouse’sl e f th i n dp a w .
Unpublished data from our lab indicate that a single i.p.
injection of 150 mg/kg of ZJ43 inhibits NAAG peptidase
inhibition for no more than 6 hours (Olszewski R, Ball
S, Wegorzewska M, Lee M, Janczura K, Neale JH in pre-
paration). As a result, in this dual injection paradigm
there would be no significant peptidase inhibition
ongoing at the time of behavioral testing or assessment
of the brain slices at 24 hours post inflammation. The
ZJ43 treated animals were divided into two groups: (1)
used in electrophysiology experiments and (2) used in
mechanical threshold (von Frey) experiments 24 hours
post formalin injection.
Electrophysiology
Coronal brain slices (300 μM) (Bregma -1.06 to -1.58
mm) containing the right central nucleus of amygdala,
laterocapsular part (CeLC) were prepared using techni-
ques that emulate those used in rats [52,62]. Briefly,
mice (i.e. postnatal day 17-25, C57BL/6, Taconic Lab.)
were decapitated, and the brain rapidly removed and
placed in ice cold sucrose containing artificial cerebrosp-
inal fluid (ACSF) buffer. No anesthesia was used prior to
decapitation to avoid contamination of the brain tissue.
Brain slices were then prepared using a micro slicer
vibratome 3000 (Vibratome Inc, St Louis MO) and incu-
bated at 32°C for 30 minutes in a sucrose based (ACSF)
(mM): (NaCl 86, KCl 3, MgCl2 4, NaH2PO4 1, sucrose
75, glucose 25, CaCl2 1, NaHCO3 25). Slices were then
maintained at 32°C for 30 minutes in standard ACSF of
the following composition (mM): (NaCl 124, KCL 4.5,
MgCl2 1, NaH2PO4 1, glucose 10, CaCl2 2, NaHCO3
26). The slice bathing medium was bubbled with O2/
CO2 at a composition of 95% and 5%. After the incuba-
tion period, slices were transferred to the recording
chamber and, unless stated otherwise, were perfused at
2 ml/min with a nominally Mg
2+ free extracellular solu-
tion (Mg
2+ was omitted from the standard ACSF). All
experiments were performed at 30 ± 2°C in the presence
of picrotoxin (30 μM, Sigma Aldrich St Louis, MO) and
CGP52432 (10 μM, Tocris Bioscience Ellisville, MO) to
block GABAergic currents. D-serine a co-agonist at gly-
cine site on NMDA receptor (10 μM, Sigma) was
included in nominal Mg
2+ free extracellular solution.
Coronal brain slices were obtained from untreated con-
trol mice, saline treated mice (24 hours post injection),
ZJ43 treated formalin mice, and formalin-treated mice
at 1, 6 and 24 hours post footpad injection. Using video
as a visual guide the stimulating electrode was posi-
tioned on the fibers dorsomedial to the CeA and ventral
to but outside the caudaputamen, (see fig 8A in [63]).
The spinoparabrachial amygdaloid (PB-CeA) afferents
reaching the central nucleus of the amygdala were sti-
mulated using a tungsten bipolar stimulating electrode
at a frequency of 0.1 Hz. Stimulation of the afferents in
the external capsule (EC), which sends cortical inputs
that originate outside of the pain pathway (PB-CeA) to
the amygdala was used as a control for input specificity.
Recordings were made from neurons in the anterior
part of the CeLC region.
Input-output experiments [63,64] were used to assess
the synaptic strength response to incremental increases
in stimulus intensity (0.08-5 mA) in the CeLC region
and to compare changes in synaptic transmission
between treatment groups. The same intensities were
used for each animal group; the maximum stimulus
intensity was that which failed to further increase the
eEPSCs size. Current clamp experiments, with increas-
ing depolarizing current injections of 20 pA steps were
performed. Rheobase current was defined as the first
current step, within a series of increasing 20 pA steps
that elicited an action potential.
Electrodes were pulled in two stages on a vertical pip-
ette puller from borosilicate glass capillaries (Wiretrol II,
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composition (mM) was: (Kgluconate 145, EGTA 5,
MgCl2 5 ,H E P E S1 0 ,A T P - N a5 ,G T P - N a0 . 2 ,a n dp H
7.2 with KOH). For the input-output experiments, the
local anesthetic QX-314 (5 mM) was included in the
pipette solution to block voltage gated Na
+ conductance.
Typical pipette resistance was 5-7 MΩ. Whole-cell
recordings at Vhold = -60 mV were performed with a
patch-clamp amplifier (Axopatch 200B, Axon Instru-
ment, Foster City, CA) under video visual control with a
Nikon Eclipse E600FN microscope (Nikon Japan).
Drugs
Urea based glutamate carboxypeptidase (GCP) inhibitor
N-[N-[(S)]-1, 3-dicarboxypropyl] carbamoyl]-L-leucine
(ZJ43) was provided by Dr Alan Kozikowski at Univer-
sity of Illinois Chicago. At concentrations as high as 10
μM, ZJ43 fails to act as an agonist or antagonist at
group I, II and III mGluRs [13]. The group II metabo-
tropic glutamate receptor (mGluR) antagonist
(LY341495), the GABAB antagonist (CGP 52432), the
AMPA receptor antagonist [sodium-2, 3-dihydro-6-
nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX)], NMDA
receptor antagonist receptor antagonist [3-[(±)-2-carbox-
ypiperazin-4-yl]-propyl-1-phosphonic acid (CPP)], and
tetrodotoxin (TTX) were from Tocris Bioscience (Ellis-
ville, MO). N-acetylaspartylglutamate (NAAG) from
Tocris. We have long recognized that commercial
NAAG is contaminated with 0.1-0.4% glutamate. As a
result for more than a decade, we have routinely re-pur-
ified by ion exchange chromatography to remove traces
of glutamate contamination (final glutamate levels less
than 0.1%). The group II mGluR agonist SLx-3095-1
[see [16] was the generous gift of Alessandra Bartolozzi
at Surface Logix, Inc. Boston, MA. SLx-3095-1 is the
racemate (+/- isomer as HCl salt) of the highly selective
group II mGluR agonist LY379268 (- isomer). Its synth-
esis is described as compound 9 in [65].
Stock solutions of TTX, NBQX, picrotoxin and CPP
were dissolved in water. ZJ43, LY341495, and SLx-3095-
1 were dissolved in saline. NAAG was dissolved in equi-
molar NaOH. CGP52432 was dissolved in dimethylsulf-
oxide (DMSO) at 0.01% final concentration.
Drug application
The recording chamber was perfused continuously with
nominal Mg
2+ free or standard ACSF in order to mini-
mize spread of the drug beyond the application site.
Drugs were diluted in the recording ACSF to obtain
optimal concentrations. All drugs solutions were locally
applied adjacent to the recording site via a Y-tube [66]
for 5 minutes and modified for optimal solution
exchange in brain slices [67]. AMPA receptor antagonist
(NBQX, 5 μM) or NMDA receptor antagonist (CPP, 10
μM) were used at the end each experiment based on the
type of current being measured to confirm the proper Y
tube placement relative to the recording site.
Data analysis
Spontaneous and miniature excitatory postsynaptic cur-
rents (sEPSCs and mEPSCs) were identified with semi-
automated template based analysis software in Clampfit
9.2 or using a semi-automated threshold based mini
detection software (Mini Analysis, Synaptosoft Inc.,
http://www.synaptosoft.co m ,F o r tL e e ,N J )a n dv i s u a l l y
confirmed. Event detection threshold was set at 5 times
the root mean square level of baseline noise. mEPSC
and sEPSC averages were based on ≥30 events in each
cell studied and the decay kinetics were determined
using exponential curve fitting. Evoked excitatory post-
synaptic currents (eEPSCs) inhibited or enhanced by
various pharmacological agents are represented as abso-
lute magnitude and were determined by comparison of
mean baseline before and immediately after drug appli-
cation. Failures were excluded from evoked current ana-
lysis. The change in the peak of the Gaussians was
calculated to determine the drug effect. Cells with
> 20% change in access resistance were discarded. Off-
line evoked current data analysis, curve fitting, and figure
preparation was performed using Clampfit 9.2 (Molecular
Devices, Inc. Sunnyvale CA) and Microsoft excel.
TWL and mechanical WT values were obtained from
the digital readout of the Hargreaves plantar and EVF
apparatus respectively.
Statistical significance was determined using a two-
tailed Student’s t-test unpaired when comparing two
populations of cells, and paired when comparing condi-
tions in the same cell population or animal group. In
ZJ43 response experiments one way repeated measure-
analysis of variance (RM-ANOVA) was followed by pair-
wise Tukey t-test post hoc analysis (Sigmaplot 11 soft-
ware, http://www.sigmaplot.com).
In the von Frey experiments, differences between the
three groups (saline, formalin and naïve) and changes
over time were analyzed for ipsilateral and contralateral
hindpaw with a two way RM-ANOVA, followed by
Tukey post-hoc comparisons between groups. Signifi-
cant changes post-injection were established by compar-
ison with baseline values (pre-injection) using Student’s
t-test for paired data. In each group of the von Frey
experiments, differences between contralateral and ipsi-
lateral sides to injection were tested over time with a
two way RM-ANOVA. Two way RM-ANOVA analysis
was used to analysis changes in TWL over time. The
Tukey t-test post-hoc analysis was used for multiple
comparisons between groups. All data are presented as
mean ± SEM. The significance levels were set at *p ≤
0.05. In all figures, *p ≤ 0.05 and **p ≤ 0.005 compared
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term “control” when applied to brain slices or treatment
groups refers to untreated mice.
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